Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?
Marilyn C. Pike(Bethesda Hospital), Lexy Kelley(UCB Pharma (United States))
Cited by 14
Related Papers
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
|Circulation|2002|652
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
|Annals of the Rheumatic Diseases|2013|340
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure
|Kidney International|1999|305